Mikami Shuji, Oya Mototsugu, Shimoda Masayuki, Mizuno Ryuichi, Ishida Masaru, Kosaka Takeo, Mukai Makio, Nakajima Motowo, Okada Yasunori
Division of Diagnostic Pathology, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan.
Clin Cancer Res. 2008 Oct 1;14(19):6055-61. doi: 10.1158/1078-0432.CCR-08-0750. Epub 2008 Sep 22.
Heparanase activity has been detected in many malignant tumors, showing a correlation with the metastatic potential. The present study was undertaken to investigate the expression of heparanase and its prognostic significance in renal cell carcinomas (RCC).
Nineteen RCCs and 6 nonneoplastic renal tissues were analyzed for heparanase mRNA expression by real-time PCR. Heparanase protein expression was semiquantitatively investigated by immunohistochemistry in 70 RCCs. Involvement of heparanase in the invasiveness of RCC cell lines, 786-O and Caki-2 cells, was examined by down-regulating the gene expression with small interfering RNA (siRNA) using the Matrigel invasion assay.
The expression level of heparanase mRNA was significantly higher in clear cell RCCs than in papillary RCCs, chromophobe RCCs, and nonneoplastic renal tissues. Heparanase was predominantly immunolocalized to cell surface and cytoplasm of clear cell RCCs and mean expression levels of heparanase were significantly higher in clear cell RCCs than in papillary and chromophobe RCCs. The protein expression levels were positively correlated with primary tumor stage, distant metastasis, and histologic grade. Targeting of heparanase mRNA expression in 786-O and Caki-2 cells with siRNA down-regulated the mRNA expression and inhibited the Matrigel invasion by these cells, whereas nonsilencing siRNA showed no effect. Multivariate Cox analysis revealed that elevated heparanase expression was a significant and an independent predictor of disease-specific survival (odds ratio, 8.814; P = 0.019).
These data suggest that heparanase plays an important role in invasion and metastasis and silencing of the gene might be a potential therapeutic target in clear cell RCCs.
已在多种恶性肿瘤中检测到乙酰肝素酶活性,其与转移潜能相关。本研究旨在探讨乙酰肝素酶在肾细胞癌(RCC)中的表达及其预后意义。
采用实时PCR分析19例RCC和6例非肿瘤性肾组织中乙酰肝素酶mRNA的表达。通过免疫组织化学对70例RCC进行乙酰肝素酶蛋白表达的半定量研究。使用基质胶侵袭试验,通过小干扰RNA(siRNA)下调基因表达,检测乙酰肝素酶在RCC细胞系786 - O和Caki - 2细胞侵袭中的作用。
透明细胞RCC中乙酰肝素酶mRNA的表达水平显著高于乳头状RCC、嫌色细胞RCC和非肿瘤性肾组织。乙酰肝素酶主要免疫定位于透明细胞RCC的细胞表面和细胞质,透明细胞RCC中乙酰肝素酶的平均表达水平显著高于乳头状和嫌色细胞RCC。蛋白表达水平与原发肿瘤分期、远处转移和组织学分级呈正相关。用siRNA靶向786 - O和Caki - 2细胞中的乙酰肝素酶mRNA表达可下调mRNA表达并抑制这些细胞的基质胶侵袭,而非沉默siRNA则无作用。多因素Cox分析显示,乙酰肝素酶表达升高是疾病特异性生存的显著且独立预测因子(比值比,8.814;P = 0.019)。
这些数据表明乙酰肝素酶在侵袭和转移中起重要作用,该基因的沉默可能是透明细胞RCC的潜在治疗靶点。